Sagimet Biosciences Inc (SGMT)
4.34
+0.05
(+1.17%)
USD |
NASDAQ |
May 07, 16:00
4.34
0.00 (0.00%)
After-Hours: 17:15
Sagimet Biosciences Cash from Financing (Quarterly): 0.00 for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.00 |
| September 30, 2023 | 87.21M |
| June 30, 2023 | -0.91M |
| March 31, 2023 | -0.136M |
| December 31, 2022 | -0.055M |
| Date | Value |
|---|---|
| September 30, 2022 | 0.00 |
| June 30, 2022 | -0.03M |
| March 31, 2022 | 0.012M |
| March 31, 2021 | 11.14M |
| March 31, 2020 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.91M
Minimum
Jun 2023
87.21M
Maximum
Sep 2023
9.724M
Average
--
Median
Mar 2020
Cash from Financing (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | 479.92M |
| 89bio Inc | 162.17M |
| Viking Therapeutics Inc | 606.04M |
| Akero Therapeutics Inc | 0.502M |
| Arrowhead Pharmaceuticals Inc | 0.267M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -7.083M |
| Cash from Investing (Quarterly) | -19.62M |
| Free Cash Flow | -23.77M |
| Free Cash Flow Per Share (Quarterly) | -0.3094 |
| Free Cash Flow Yield | -25.64% |